DNA, Anticancer therapies, synthesis, ruthenium
Cancer Biology | Chemistry | Inorganic Chemistry | Oncology
Side effects associated with platinum-based anticancer therapies have resulted in the search for novel nonplatinum-based metal species. Among the different metal complexes generating interest, rutheniumII complexes have shown great potential as anticancer agents. A series of mixed ligand ruthenium complexes with he formula cis-[Ru(X)(HPB)(OH2)], where X corresponds to either (1) Terpy = 2,2':6',2"-terpyridine; (2) Pheterpy = 4' -Phenyl-2,2':6',2"-terpyridine or (3) Tterpy = 4'-Tolyl-2,2':6',2"-terpyridine, and HPB = 2-(2' -hydroxyphenyl)-benozoxazole, have been synthesized and structurally characterized. The DNA binding of the rutheniumII complexes has been studied using several physical methods including absorption spectroscopy and competitive binding displacement assays. The abilit of the complexes to unwind and / or untwist DNA has also been studied using supercoiled pUC18 DNA.
Department 1 Awarding Honors Status
Jonkhoff, N. M. (2011). The Synthesis and Characterization of Novel Ruthenium Terpyridine Complexes: Reactivity with DNA (Undergraduate honors thesis, University of Redlands). Retrieved from https://inspire.redlands.edu/cas_honors/496
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License